Updates are available Correction dated 2023-05-25

Article History

Received: 27 October 2022

Revised: 22 February 2023

Accepted: 1 March 2023

First Online: 17 March 2023

Change Date: 25 May 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41375-023-01927-8

Competing interests

: PSK, TW, LR, AJP, AZ, MP, LA have no conflicts to disclose. SAB receives research funding from AstraZeneca, and has consulted for Pharmacyclics, Janssen, Beigene, and AstraZeneca, and has received honorarium from OncLive, and has received travel funding from Arqule. JCB has consulted for Syndax, Trillium, AstraZeneca, Novartis, Newave and Kronos, and is the chair of the scientific advisory board and a major stockholder in Vincerx Pharma. MRG receives research funding from the Hairy Cell Leukemia Foundation for Patient Data Registry, has consulted AstraZeneca, Pharmacyclics, Ascerta (participant in long-term follow-up Data Safety Monitoring Committee), Axio, Inc; Serono/Merck, has received travel expenses from the Hairy Cell Leukemia Foundation, is the scientific board chair for the Hairy Cell Leukemia Foundation Scientific Board (no reimbursement), and has received scientific honorarium from the University of Pittsburgh. KAR receives research funding from Genentech, AbbVie, Janssen, and Novartis, consults for AbbVie, AstraZeneca, Genentech, Pharmacyclics, Innate Pharma, and Beigene, and received travel funding from AstraZeneca. JAW has received research funding from Janssen, Morphosys, and Schrodinger and has consulted for Abbvie, AstraZeneca, Beigene, Genentech, Janssen, Loxo, Newave, and Pharmacyclics. ASK has received research funding from AstraZeneca, and has consulted for Abbvie, AstraZeneca, Beigene, KITE, and Janssen.